Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2015, Article ID 676191, 4 pages
http://dx.doi.org/10.1155/2015/676191
Case Report

Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient

Southside Endocrinology, 3928 Montclair Road, Suite 130, Mountain Brook, AL 35213, USA

Received 4 November 2014; Revised 3 February 2015; Accepted 6 February 2015

Academic Editor: Toshihiro Kita

Copyright © 2015 David S. H. Bell. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. R. Henry, J. Rosenstock, and A. Chalamandaris, “Exploring the potential of dapagliflozin in type 1 diabetes: phase 2a pilot study,” Diabetes, vol. 62, supplement 1A, abstract 70, 2013. View at Google Scholar
  2. B. A. Perkins, D. Z. I. Cherney, H. Partridge et al., “Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial,” Diabetes Care, vol. 37, no. 5, pp. 1480–1483, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Z. I. Cherney, B. A. Perkins, N. Soleymanlou et al., “The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus,” Cardiovascular Diabetology, vol. 13, article 28, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Z. I. Cherney, B. A. Perkins, N. Soleymanlou et al., “Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus,” Circulation, vol. 129, no. 5, pp. 587–597, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. R. A. DeFronzo, M. Hompesch, S. Kasichayanula et al., “Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes,” Diabetes Care, vol. 36, no. 10, pp. 3169–3176, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Vouyiouklis, “Canagliflozin: improving diabetes by making urine sweet,” Cleveland Clinic Journal of Medicine, vol. 80, no. 11, pp. 683–687, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Monnier, H. Lapinski, and C. Colette, “Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c,” Diabetes Care, vol. 26, no. 3, pp. 881–885, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. D. S. H. Bell, J. H. O'Keefe, and P. Jellinger, “Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events?” Endocrine Practice, vol. 14, no. 1, pp. 112–124, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Nalysnyk, M. Hernandez-Medina, and G. Krishnarajah, “Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature,” Diabetes, Obesity and Metabolism, vol. 12, no. 4, pp. 288–298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Schiffrin, S. Suissa, P. Poussier, R. Guttmann, and G. Weitzner, “Prospective study of predictors of β-cell survival in type I diabetes,” Diabetes, vol. 37, no. 7, pp. 920–925, 1988. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Luippold, T. Klein, M. Mark, and R. Grempler, “Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus,” Diabetes, Obesity and Metabolism, vol. 14, no. 7, pp. 601–607, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Schatz, “Metformin in type 1 diabetes reduces insulin requirements without significantly improving glycaemic control,” Diabetologia, vol. 53, no. 10, pp. 2264–2265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Pandey, V. Forte, M. Abdallah et al., “Diabetes mellitus and the risk of cancer,” Minerva Endocrinologica, vol. 36, no. 3, pp. 187–209, 2011. View at Google Scholar · View at Scopus
  14. J.-W. Yoon, H.-S. Jun, and P. Santamaria, “Cellular and molecular mechanisms for the initiation and progression of β cell destruction resulting from the collaboration between macrophages and T cells,” Autoimmunity, vol. 27, no. 2, pp. 109–122, 1998. View at Publisher · View at Google Scholar · View at Scopus